ACI 24

Drug Profile

ACI 24

Alternative Names: ACI-24; Anti-Abeta vaccine - AC immune; Pal1-15 acetate salt

Latest Information Update: 11 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AC Immune
  • Developer AC Immune; University of California, San Diego
  • Class Alzheimer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 05 Apr 2016 Phase-Ib clinical trials in Alzheimer's disease in USA, Switzerland (SC)
  • 07 Jan 2016 AC Immune in collaboration with University of California San Diego plans a phase Ib trial for Alzheimer's disease-like characteristics in Down syndrome in USA and Switzerland
  • 16 Sep 2015 Phase-I/IIa development for Alzheimer's disease is ongoing in Denmark, Finland and Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top